New developments in the genetics, pathogenesis, and therapy of IgA nephropathy

Kidney International

Volumn 88, Issue 5, 2015, Pages 974-989

  Magistroni, Riccardo ^a,b   D'Agati, Vivette D ^a   Appel, Gerald B ^a   Kiryluk, Krzysztof ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adaptive immunity; Complement system; GWAS; IgA nephropathy; Innate immunity; O glycosylation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBODY; ATACICEPT; AZATHIOPRINE; BLISIBIMOD; BORTEZOMIB; BUDESONIDE; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSTAMATINIB; GLYCAN ANTIBODY; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; N ACETYLGALACTOSAMINE;

ALLELE; ANTIGEN ANTIBODY COMPLEX; BIOACCUMULATION; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; CONSENSUS; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; GENE LOCUS; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNOBIOLOGY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INCIDENCE; INFLAMMATION; INTESTINE EPITHELIUM; KIDNEY BIOPSY; NONHUMAN; POPULATION GENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN GLYCOSYLATION; PROTEINURIA; REVIEW; SCORING SYSTEM; TRANSLATIONAL RESEARCH; GENETICS; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; IMMUNOLOGY; METABOLISM;

ACETYLGALACTOSAMINE; COMPLEMENT SYSTEM PROTEINS; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; PROGNOSIS;

EID: 84947613551     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.252     Document Type: Review

References (200)

1. Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol 1968; 74: 694-695.
2. Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol 2014; 10: 445-454.
3. Working Group of the International Ig ANN, the Renal Pathology S, Roberts IS et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
4. Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis 1988; 12: 348-352.
5. Valentijn RM, Radl J, Haaijman JJ et al. Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int 1984; 26: 760-766.
6. Haas M. IgA nephropathy and Henoch-Schonlein Purpura Nephritis. In: Jennette JC, D'Agati VD, Olson JL et al. (eds). Heptinstall's Pathology of the Kidney, 7th edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2015. , pp 475-524.
7. Chui SH, Lam CW, Lewis WH et al. Light-chain ratio of serum IgA1 in IgA nephropathy. J Clin Immunol 1991; 11: 219-223.
8. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842.
9. Hill GS, Karoui KE, Karras A et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. Immunohistochemical studies. Kidney Int 2011; 79: 635-642.
10. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumat 2013; 65: 1-11.
11. Pillebout E, Thervet E, Hill G et al. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13: 1271-1278.
12. Lee SM, Rao VM, Franklin WA et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol 1982; 13: 314-322.
13. Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
14. Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80: 310-317.
15. Yau T, Korbet SM, Schwartz MM et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol 2011; 34: 435-444.
16. Alamartine E, Sauron C, Laurent B et al. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 2011; 6: 2384-2388.
17. Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 2012; 27: 715-722.
18. El Karoui K, Hill GS, Karras A et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79: 643-654.
19. Gutierrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012; 23: 1753-1760.
20. Zeng CH, Le W, Ni Z et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis 2012; 60: 812-820.
21. Katafuchi R, Ninomiya T, Nagata M et al. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011; 6: 2806-2813.
22. Kang SH, Choi SR, Park HS et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant 2012; 27: 252-258.
23. Shi SF, Wang SX, Jiang L et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 2011; 6: 2175-2184.
24. Shima Y, Nakanishi K, Hama T et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 2012; 27: 783-792.
25. Kataoka H, Ohara M, Shibui K et al. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 2012; 16: 706-712.
26. Moriyama T, Nakayama K, Iwasaki C et al. Severity of nephrotic IgA nephropathy according to the Oxford classification. Int Urol Nephrol 2012; 44: 1177-1184.
27. Lee H, Yi SH, Seo MS et al. Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults. Korean J Intern Med 2012; 27: 293-300.
28. Le W, Zeng CH, Liu Z et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol 2012; 13: 158.
29. Working Group of the International Ig ANN, the Renal Pathology S, Coppo R et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77: 921-927.
30. Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86: 828-836.
31. Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int 2014; 85: 779-793.
32. Lv J, Shi S, Xu D et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2013; 62: 891-899.
33. Sinniah R. Occurrence of mesangial IgA and IgM deposits in a control necropsy population. J Clin Pathol 1983; 36: 276-279.
34. Waldherr R, Rambausek M, Duncker WD et al. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4: 943-946.
35. Varis J, Rantala I, Pasternack A. Immunofluorescence of immunoglobulins and complement in kidneys taken at necropsy. J Clin Pathol 1989; 42: 1211-1214.
36. Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286-2294.
37. Demircin G, Delibas A, Bek K et al. A one-center experience with pediatric percutaneous renal biopsy and histopathology in Ankara, Turkey. Int Urol Nephrol 2009; 41: 933-939.
38. Monfared A, Khosravi M, Lebadi M et al. Distribution of renal histopathology in Guilan: a single-center report. Iran J Kidney Dis 2012; 6: 173-177.
39. Berthoux F. Annual incidence of glomerulonephritis in the extended Rhone-Alpes region in 1987-1988. Presse Med 1990; 19: 1417.
40. Gesualdo L, Di Palma AM, Morrone LF et al. The Italian experience of the national registry of renal biopsies. Kidney Int 2004; 66: 890-894.
41. Hanko JB, Mullan RN, O'Rourke DM et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009; 24: 3050-3054.
42. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997; 12: 418-426.
43. Kurnatowska I, Jedrzejka D, Malyska A et al. Trends in the incidence of biopsy-proven glomerular diseases in the adult population in central Poland in the years 1990-2010. Kidney Blood Pressure Res 2012; 35: 254-258.
44. Sugiyama H, Yokoyama H, Sato H et al. Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 2011; 15: 493-503.
45. Zhou FD, Zhao MH, Zou WZ et al. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 2009; 24: 870-876.
46. McQuarrie EP, Mackinnon B, Young B et al. Centre variation in incidence, indication and diagnosis of adult native renal biopsy in Scotland. Nephrol Dial Transplant 2009; 24: 1524-1528.
47. Kiryluk K, Li Y, Sanna-Cherchi S et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 2012; 8: e1002765.
48. Okpechi I, Swanepoel C, Duffield M et al. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. Nephrol Dial Transplant 2011; 26: 1853-1861.
49. Li L. Pathological classification and clinical characteristics of primary glomerulonephritis in China: bioptic study of 1001 cases. Zhonghua yi xue za zhi 1989; 69: 20-23
50. Tojo S, Hatano M, Honda N et al. Natural history of IgA nephropathy in Japan. Semin Nephrol 1987; 7: 386-388.
51. Abdulmassih Z, Makdassi R, Bove N et al. Epidemiology of primary glomerulonephritis in Picardie. Ann Med Intern 1990; 141: 129-133.
52. Braun N, Schweisfurth A, Lohofener C et al. Epidemiology of glomerulonephritis in Northern Germany. Int Urol Nephrol 2011; 43: 1117-1126.
53. Browne O, Doyle GD, Campbell E. An immunohistological study of IgA nephropathy and a report of its incidence in Ireland. Irish J Med Sci 1985; 154: 461-465.
54. Carvalho E, do Sameiro Faria M, Nunes JP et al. Renal diseases: a 27-year renal biopsy study. J Nephrol 2006; 19: 500-507.
55. Fisi V, Mazak I, Degrell P et al. Histological diagnosis determines complications of percutaneous renal biopsy: a single-center experience in 353 patients. Kidney Blood Pressure Res 2012; 35: 26-34.
56. Heaf J, Lokkegaard H, Larsen S. The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997. Nephrol Dial Transplant 1999; 14: 1889-1897.
57. Mesquita M, Fosso C, Bakoto Sol E et al. Renal biopsy findings in Belgium: a retrospective single center analysis. Acta Clin Belg 2011; 66: 104-109.
58. Mustonen J, Pasternack A, Helin H et al. Circulating immune complexes, the concentration of serum IgA and the distribution of HLA antigens in IgA nephropathy. Nephron 1981; 29: 170-175.
59. Riispere Z, Ots-Rosenberg M. Occurrence of kidney diseases and patterns of glomerular disease based on a 10-year kidney biopsy material: a retrospective single-centre analysis in Estonia. Scand J Urol Nephrol 2012; 46: 389-394.
60. Rivera F, Lopez-Gomez JM, Perez-Garcia R et al. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66: 898-904.
61. Schmekel B, Svalander C, Bucht H et al. Mesangial IgA glomerulonephritis in adults. Clinical and histopathological observations. Acta Med Scand 1981; 210: 363-372.
62. Tiebosch AT, Wolters J, Frederik PF et al. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int 1987; 32: 112-116.
63. Radford MG Jr, Donadio JV Jr, Bergstralh EJ et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207.
64. Knoop T, Vikse BE, Svarstad E et al. Mortality in patients with IgA nephropathy. Am J Kidney Dis 2013; 62: 883-890.
65. Feehally J, Cameron JS. IgA nephropathy: progress before and since Berger. Am J Kidney Dis 2011; 58: 310-319.
66. Lee H, Hwang JH, Paik JH et al. Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC Nephrol 2014; 15: 94.
67. Chandrika BK. IgA nephropathy in Kerala, India: a retrospective study. Indian J Pathol Microbiol 2009; 52: 14-16.
68. O'Connell PJ, Ibels LS, Thomas MA et al. Familial IgA nephropathy: a study of renal disease in an Australian aboriginal family. Austral NZ J Med 1987; 17: 27-33.
69. Levy M. Familial cases of Berger's disease and anaphylactoid purpura: more frequent than previously thought. Am J Med 1989; 87: 246-248.
70. Julian BA, Quiggins PA, Thompson JS et al. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 1985; 312: 202-208.
71. Scolari F, Amoroso A, Savoldi S et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis 1999; 33: 857-865.
72. Paterson AD, Liu XQ, Wang K et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol 2007; 18: 2408-2415.
73. Karnib HH, Sanna-Cherchi S, Zalloua PA et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant 2007; 22: 772-777.
74. Masuda J, Shiiki H, Fujii Y et al. Identical twin sisters with IgA nephropathy. Nihon Jinzo Gakkai shi 1996; 38: 52-56.
75. Tsuboi N, Kawamura T, Okonogi H et al. Discordant clinicopathological features in monozygotic twins with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 4146-4148.
76. Ahlmen J, Hedman I, Svalander C. Recurrent IgA-nephropathy in an identical twin transplant. Clin Transplant 1989: 297.
77. Schena FP, Scivittaro V, Ranieri E et al. Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol 1993; 92: 139-144.
78. Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1008-1014.
79. Kiryluk K, Moldoveanu Z, Sanders JT et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int 2011; 80: 79-87.
80. Gharavi AG, Yan Y, Scolari F et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354-357.
81. Bisceglia L, Cerullo G, Forabosco P et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79: 1130-1134.
82. Maher B. Personal genomes: the case of the missing heritability. Nature 2008; 456: 18-21.
83. Feehally J, Farrall M, Boland A et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21: 1791-1797.
84. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
85. Yu XQ, Li M, Zhang H et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2012; 44: 178-182.
86. Kiryluk K, Li Y, Scolari F et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46: 1187-1196.
87. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010; 34: J168-J177.
88. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010; 9: A355-A365.
89. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: A387-A394.
90. Handel AE, Handunnetthi L, Giovannoni G et al. Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol 2010; 17: 1210-1214.
91. Pullan RL, Smith JL, Jasrasaria R et al. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit Vectors 2014; 7: 37.
92. Barry MA, Simon GG, Mistry N et al. Global trends in neglected tropical disease control and elimination: impact on child health. Arch Dis Childhood 2013; 98: 635-641.
93. Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795-1803.
94. Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med 2013; 64: 339-356.
95. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest 2014; 124: 2325-2332.
96. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677.
97. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol 2012; 12: 821-832.
98. Mestecky J, Raska M, Julian BA et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 2013; 8: 217-240.
99. Allen AC, Harper SJ, Feehally J. Galactosylation of N-and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995; 100: 470-474.
100. Novak J, Julian BA, Tomana M et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008; 28: 78-87.
101. Hiki Y, Horii A, Iwase H et al. O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role. Contrib Nephrol 1995; 111: 73-84.
102. Moldoveanu Z, Wyatt RJ, Lee JY et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71: 1148-1154.
103. Zhao N, Hou P, Lv J et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012; 82: 790-796.
104. Hastings MC, Moldoveanu Z, Julian BA et al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 2010; 5: 2069-2074.
105. Smith AC, de Wolff JF, Molyneux K et al. O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 2006; 17: 1192-1199.
106. Suzuki H, Moldoveanu Z, Hall S et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008; 118: 629-639.
107. Boyd JK, Cheung CK, Molyneux K et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012; 81: 833-843.
108. Buren M, Yamashita M, Suzuki Y et al. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 2007; 157: 50-55.
109. Batra A, Smith AC, Feehally J et al. T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 2007; 22: 2540-2548.
110. Kennel-De March A, Bene MC, Hurault de Ligny B et al. Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clin Immunol Immunopathol 1997; 84: 158-165.
111. Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109: 1587-1598.
112. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26: 812-826.
113. Castigli E, Scott S, Dedeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101: 3903-3908.
114. McCarthy DD, Kujawa J, Wilson C et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 2011; 121: 3991-4002.
115. Rockman SP, Demmler K, Roczo N et al. Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. J Gastroenterol Hepatol 2001; 16: 991-1000.
116. Guimbaud R, Abitbol V, Bertrand V et al. Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Eur Cytokine Netw 1998; 9: 607-612.
117. Esashi E, Ito H, Minehata K et al. Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. Eur J Immunol 2009; 39: 1664-1670.
118. Imielinski M, Baldassano RN, Griffiths A et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-1340.
119. Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
120. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
121. De Angelis M, Montemurno E, Piccolo M et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 2014; 9: e99006.
122. Harper SJ, Pringle JH, Wicks AC et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994; 45: 836-844.
123. Waldo FB. Systemic immune response after mucosal immunization in patients with IgA nephropathy. J Clin Immunol 1992; 12: 21-26.
124. Layward L, Allen AC, Hattersley JM et al. Response to mucosal antigen challenge in IgA nephropathy. Exp Nephrol 1995; 3: 300-307.
125. Roodnat JI, de Fijter JW, van Kooten C et al. Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant 1999; 14: 353-359.
126. Kiryluk K, Julian BA, Wyatt RJ et al. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol 2010; 25: 2257-2268.
127. Yanagihara T, Brown R, Hall S et al.-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol 2012; 2: 166-172.
128. Yanagawa H, Suzuki H, Suzuki Y et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 2014; 9: e98081.
129. Berthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23: 1579-1587.
130. Berthelot L, Papista C, Maciel TT et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012; 209: 793-806.
131. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003; 4: 140-156.
132. Shweke N, Boulos N, Jouanneau C et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008; 173: 631-642.
133. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002; 27: 534-539.
134. van Egmond M, van Vuuren AJ, Morton HC et al. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999; 93: 4387-4394.
135. Van Spriel AB, Leusen JH, Vile H et al. Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA. J Immunol 2002; 169: 3831-3836.
136. Floege J, Moura IC, Daha MR. New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol 2014; 36: 431-442.
137. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008; 205: 143-154.
138. Moura IC, Arcos-Fajardo M, Gdoura A et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005; 16: 2667-2676.
139. Moura IC, Arcos-Fajardo M, Sadaka C et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15: 622-634.
140. Moura IC, Centelles MN, Arcos-Fajardo M et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194: 417-425.
141. Novak J, Julian BA, Mestecky J et al. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 2012; 34: 365-382.
142. Lai KN. Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012; 8: 275-283.
143. Espinosa M, Ortega R, Sanchez M et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014; 9: 897-904.
144. Roos A, Rastaldi MP, Calvaresi N et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17: 1724-1734.
145. Goicoechea de Jorge E, Caesar JJ, Malik TH et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA 2013; 110: 4685-4690.
146. Tortajada A, Yebenes H, Abarrategui-Garrido C et al. C3 glomerulopathyassociated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 2013; 123: 2434-2446.
147. Zhu L, Zhai YL, Wang FM et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol 2014.
148. Hughes AE, Orr N, Esfandiary H et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006; 38: 1173-1177.
149. Zhao J, Wu H, Khosravi M et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079.
150. Zipfel PF, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3: e41.
151. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; 2: 139-274.
152. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888.
153. Li PK-T, Leung CB, Chow KM et al. Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): a double-blind, randomized, placebocontrolled study. Am J Kidney Dis 2006; 47: 751-760.
154. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
155. Horita Y, Tadokoro M, Taura K et al. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Renal Fail 2007; 29: 441-446.
156. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-856.
157. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-887.
158. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163.
159. Manno C, Torres DD, Rossini M et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701.
160. Lv J, Xu D, Perkovic V et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 1108-1116.
161. Strippoli GF, Maione A, Schena FP et al. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice. Am J Kidney Dis 2009; 53: 5-8.
162. Komatsu H, Fujimoto S, Sato Y et al. 'Point of no return (PNR)' in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. J Nephrol 2005; 18: 690-695.
163. Tang Z, Wu Y, Wang QW et al. Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol 2002; 22: 480-486.
164. Abe T, Kida H, Yoshimura M et al. Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol 1986; 25: 37-41.
165. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-1329.
166. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Medi 2010; 363: 221-232.
167. Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-427.
168. Pozzi C, Andrulli S, Pani A et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21: 1783-1790.
169. Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990; 34: 45-51.
170. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990; 89: 209-215.
171. Xie J, Kiryluk K, Wang W et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 2012; 7: e38904.
172. Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86: 828-836.
173. Magistroni R, Furci L, Leonelli M et al. A validated model of disease progression in IgA nephropathy. J Nephrol 2006; 19: 32-40.
174. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997; 29: 526-532.
175. Katafuchi R, Oh Y, Hori K et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol 1994; 41: 191-198.
176. Okada H, Suzuki H, Konishi K et al. Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol 1992; 37: 235-238.
177. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237.
178. Smerud HK, Barany P, Lindstrom K et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26: 3237-3242.
179. International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353-1360.
180. Visscher PM, Brown MA, McCarthy MI et al. Five years of GWAS discovery. Am J Hum Genet 2012; 90: 7-24.
181. Visekruna A, Joeris T, Seidel D et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006; 116: 3195-3203.
182. Wu F, Dassopoulos T, Cope L et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis 2007; 13: 807-821.
183. Schmidt N, Gonzalez E, Visekruna A et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010; 59: 896-906.
184. Fujimoto K, Karuppuchamy T, Takemura N et al. A new subset of CD103 +CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 2011; 186: 6287-6295.
185. Uematsu S, Fujimoto K, Jang MH et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008; 9: 769-776.
186. Hom G, Graham RR, Modrek B et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358: 900-909.
187. Bertin J, Guo Y, Wang L et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem 2000; 275: 41082-41086.
188. Sokol H, Conway KL, Zhang M et al. Card9 mediates intestinal epithelial cell restitution, T-helper 17 responses, and control of bacterial infection in mice. Gastroenterology 2013; 145: 591-601, e3.
189. Beaudoin M, Goyette P, Boucher G et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet 2013; 9: e1003723.
190. Rivas MA, Beaudoin M, Gardet A et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-1073.
191. Lanternier F, Pathan S, Vincent QB et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013; 369: 1704-1714.
192. Vigorito E, Gambardella L, Colucci F et al. Vav proteins regulate peripheral B-cell survival. Blood 2005; 106: 2391-2398.
193. Liu JY, Seno H, Miletic AV et al. Vav proteins are necessary for correct differentiation of mouse cecal and colonic enterocytes. J Cell Sci 2009; 122: 324-334.
194. Levison SE, Fisher P, Hankinson J et al. Genetic analysis of the Trichuris muris-induced model of colitis reveals QTL overlap and a novel gene cluster for establishing colonic inflammation. BMC Genom 2013; 14: 127.
195. Eriksson N, Tung JY, Kiefer AK et al. Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One 2012; 7: e34442.
196. Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-829.
197. Osman W, Okada Y, Kamatani Y et al. Association of common variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and immunoglobulin isotypes in Japanese. PLoS One 2012; 7: e32683.
198. Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829-834.
199. Kalabis J, Patterson MJ, Enders GH et al. Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagenembedded fibroblasts in organotypic culture. FASEB J 2003; 17: 1115-1117.
200. Ernst M, Inglese M, Waring P et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 2001; 194: 189-203.